<DOC>
	<DOCNO>NCT02088931</DOCNO>
	<brief_summary>The purpose study test safety experimental therapy single infusion Regulatory T cell ( Tregs ) . The investigator want find effect , good bad , Tregs kidney transplant patient . There different type T cell . This study use Regulatory T cell ( Tregs ) , find blood part immune system stop immune cell work . Tregs help turn immune system immune cell finish tackle outside infection , Tregs keep immune system check body attack . The researcher hop , give infusion Tregs attack kidney stop kidney function stabilize . It known Treg experimental therapy stop inflammation kidney . In study , researcher take Tregs patient , multiply laboratory , infuse back patient . The procedure use multiply Tregs experimental process perform laboratory . Similar procedure do mice show reverse inflammation know whether result human . This therapy yet do human outside research study .</brief_summary>
	<brief_title>Treg Adoptive Therapy Subclinical Inflammation Kidney Transplantation</brief_title>
	<detailed_description>This open-label single dose pilot study 3 subject inflammation 6-month surveillance biopsy follow renal transplantation receive single infusion target 320 million cell ex vivo select expand autologous polyclonal Tregs . AAt time Treg infusion ( day 0 ) , immnosuppression remain unchanged consist tacrolimus mycophenolate acid without steroid . On follow biopsy , 2 week Treg infusion , inflammatory load assess computer assist image analysis look thenumber infiltrate cell per square mm well percentage renal cortex infiltrate lymphocyte . If inflammatory load decrease ≥50 % infused Tregs observe allograft , everolimus start 1.5 mg bid dose tacrolimus decrease 50 % . After 2 week , tacrolimus discontinue . These patient remain everolimus mycophenolic acid without prednisone end study follow period . If 2-week follow-up biopsy , decrease inflammatory load decrease &lt; 50 % , change make maintenance immunosuppressive regimen consist tacrolimus , mycophenolic acid without prednisone . immunosuppression . All prescribe physician enrol participate FDA Mycophenolate Risk Evaluation Mitigation Strategy . Subjects enrol 4-6 week interval . The first subject receive infusion observe 3 week prior treatment remain subject . The study team ( IND sponsor , protocol chair , medical monitor ) member DSMB review safety data first subject prior proceeding . If grade 3 high related adverse event observe , subsequent subject may treat . Otherwise treatment suspend pending review .</detailed_description>
	<criteria>1 . Recipients primary renal transplant age 1865 year donor specific antibody prior transplantation 2 . Stable renal function ( cGFR ) , history acute rejection proteinuria le 500 mg/24 hour . 3 . Maintenance immunosuppression consist tacrolimus mycophenolate mofetil/mycophenolic acid without prednisone 4 . Protocol renal allograft biopsy 6 month finding 5 % 25 % inflammation ( Banff t0 t1 ) without evidence rejection ( Banff t0 t1 &lt; 5 % ) 5 . Blood PCR BK less 1000 copies/ml , urine less 500,000 copies/ml 6 . History positive EBV serology 7 . Current immunization include TdAP , hepatitis B , pneumococcal seasonal influenza vaccine 1 . Recipients 6antigen HLA match kidney transplant live decease donor 2 . Subjects history prior kidney transplant 3 . History transplant renal artery stenosis 4 . History wound heal complication follow transplant surgery 5 . Known hypersensitivity tacrolimus , mycophenolate mofetil/mycophenolic acid , everolimus 6 . Subjects history autoimmune disease 7 . Hematocrit &lt; 33 % ; leukocytes &lt; 3,000/μL ; neutrophil &lt; 1,500/μL ; lymphocyte &lt; 800/μL ; platelet &lt; 100,000/μL 8 . Any current active infection 9 . Serologic evidence HIV1 HIV2 infection 10 . Evidence current hepatitis B demonstrate HBsAg circulate hepatitis B genomes 11 . Serologic evidence hepatitis C infection 12 . Detectable circulate CMV genome active infection high risk CMV ( CMV seronegative recipient receive kidney CMV seropositive donor ) 13 . Detectable circulate EBV genome 14 . History positive PPD skin test , untreated . 15 . Subjects may potentially require live virus vaccine within first 12 month study 16 . History malignancy ( include squamous cell carcinoma skin cervix ) except adequately treat basal cell carcinoma 17 . Any chronic illness prior treatment opinion investigator preclude participation trial 18 . Pregnant breastfeed woman , female unwilling use reliable effective form contraception 2 year Treg dosing , male unwilling use reliable effective form contraception 3 month Treg dose 19 . Tregs present peripheral blood less 30/µL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Tregs</keyword>
	<keyword>Kidney transplantation</keyword>
</DOC>